InflaRx, a biotech com­pany based in Jena, Ger­many, today pub­lished pos­i­tive data from its exploratory Phase IIa clin­i­cal trial with IFX‑1. The trial is for the treat­ment of hidradeni­tis sup­pu­ra­tiva (HS), a painful, chronic and inflam­ma­tory skin disease.

For more infor­ma­tion, see:
http://www.bm‑t.com/2017/inflarx-reports-topline-phase-iia-clinical-results-of-ifx-1-for-the-treatment-of-hidradenitis-suppurativa/